Liquidia Corporation

NasdaqCM:LQDA

Sector

🏥 Health Care

Industries

🔬 Clinical Trials

🧬 Biotechnology

💊 Drugstores & Retail Pharmacies

💊 Pharmaceuticals

Location

United States

Market Cap

USD 1.16 B

Share Price

USD 13.60

Avg Daily Volume

1,539,774

Change (1 day)

-1.31%

Change (1 year)

10.75%

Change (YTD)

15.65%

Liquidia Corporation Revenue for the Trailing 12 Months (TTM) ending March 31, 2025: USD 14.14 M

Liquidia Corporation Revenue is USD 14.14 M for the Trailing 12 Months (TTM) ending March 31, 2025, a -11.42% change year over year. Revenue is the total amount of money generated from the sales of goods or services by a company during a specific period.

Liquidia Corporation Revenue for the Trailing 12 Months (TTM) ending March 31, 2024 was USD 15.97 M, a -5.72% change year over year.
Liquidia Corporation Revenue for the Trailing 12 Months (TTM) ending March 31, 2023 was USD 16.94 M.

Quarterly
Annual
TTM

From:

To:

Zoom:

1Y
3Y
5Y
10Y
15Y
20Y
Max

Key data

Date	Revenue	Revenue	Gross Profit	Operating Income

NasdaqCM: LQDA

Liquidia Corporation

CEO	Dr. Roger A. Jeffs Ph.D.
IPO Date	July 26, 2018
Location	United States
Headquarters	419 Davis Drive
Employees	170
Sector	🏥 Health Care
Industries Clinical Trials 🧬 Biotechnology 💊 Drugstores & Retail Pharmacies 💊 Pharmaceuticals

Description

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.

Similar companies

Eli Lilly and Company

USD 792.30

1.83%

AbbVie Inc.

USD 185.39

-0.09%

Roche Holding AG

USD 341.12

-1.04%

AstraZeneca PLC

USD 140.14

-0.36%

Merck & Co., Inc.

USD 79.67

-0.81%

Amgen Inc.

USD 280.35

1.03%

Pfizer Inc.

USD 24.26

-0.21%

Gilead Sciences, Inc.

USD 105.93

-1.19%

Sanofi

USD 95.90

-1.25%

Bristol-Myers Squibb Company

USD 46.68

-0.74%

Chugai Pharmaceutical Co., Ltd.

USD 52.21

0.11%

GSK plc

USD 19.07

-0.64%

Cencora, Inc.

USD 292.32

-0.61%

Regeneron Pharmaceuticals, Inc.

USD 520.29

-0.38%

Jiangsu Hengrui Medicine Co., Ltd.

USD 7.29

-1.15%

Haleon plc

USD 5.22

0.20%

Takeda Pharmaceutical Company Limited

USD 30.06

0.25%

Daiichi Sankyo Company, Limited

USD 22.75

-2.17%

UCB SA

USD 196.91

2.58%

Hansoh Pharmaceutical Group Company Limited

USD 3.66

-2.04%

Insmed Incorporated

USD 104.85

-0.99%

Teva Pharmaceutical Industries Limited

USD 17.07

-0.24%

West Pharmaceutical Services, Inc.

USD 221.02

-0.74%

Summit Therapeutics Inc.

USD 21.27

1.67%

Cipla Limited

USD 17.67

0.68%

United Therapeutics Corporation

USD 285.97

-1.37%

Dr. Reddy's Laboratories Limited

USD 15.43

-1.05%

Torrent Pharmaceuticals Limited

USD 37.11

-1.05%

Sino Biopharmaceutical Limited

USD 0.65

-2.09%

CSPC Pharmaceutical Group Limited

USD 0.99

-2.38%

Zydus Lifesciences Limited

USD 11.40

0.64%

Mankind Pharma Limited

USD 26.96

0.47%

Ascendis Pharma A/S

USD 173.00

-3.41%

Viatris Inc.

USD 8.89

-0.67%

BioMarin Pharmaceutical Inc.

USD 54.14

-1.01%

Orion Oyj

USD 73.45

0.35%

Lupin Limited

USD 22.53

0.16%

Swedish Orphan Biovitrum AB (publ)

USD 29.11

0.12%

Ipsen S.A.

USD 119.73

0.43%

Huadong Medicine Co., Ltd

USD 5.62

-0.40%

Kyowa Kirin Co., Ltd.

USD 17.15

0.68%

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

USD 2.07

-0.24%

Shanghai Pharmaceuticals Holding Co., Ltd

USD 1.51

-0.50%

Abbott India Limited

USD 370.22

0.53%

Eisai Co., Ltd.

USD 27.72

1.51%

Sichuan Kelun Pharmaceutical Co., Ltd.

USD 4.89

0.65%

Shenzhen Salubris Pharmaceuticals Co., Ltd.

USD 6.45

-0.50%

Sinopharm Group Co. Ltd.

USD 2.37

0.01%

Beijing Tongrentang Co., Ltd

USD 5.12

0.41%

3SBio Inc.

USD 2.80

-1.78%

StockViz Staff

June 26, 2025

Any question? Send us an email